Stockscreener 앱 받기
4.84
7.08%
0.32
전일 마감가:
$4.52
열려 있는:
$4.56
하루 거래량:
798.02K
Relative Volume:
0.97
시가총액:
$431.44M
수익:
$380.79M
순이익/손실:
$49.27M
주가수익비율:
6.9143
EPS:
0.7
순현금흐름:
$10.68M
1주 성능:
+4.99%
1개월 성능:
+26.70%
6개월 성능:
+1.68%
1년 성능:
+164.48%
1일 변동 폭
$4.47
$4.855
1주일 범위
$4.20
$4.95
52주 변동 폭
$1.575
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
4.84 | 410.94M | 380.79M | 49.27M | 10.68M | 0.70 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Mizuho Boosts Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $8.00 - Defense World
Mizuho Adjusts Price Target on Amylyx Pharmaceuticals to $8 From $7, Maintains Outperform Rating - marketscreener.com
Amylyx price target raised to $8 from $7 at Mizuho - TipRanks
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2025 Earnings Call Transcript - Insider Monkey
Hsbc Holdings PLC Lowers Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
AMX0035 shows promise in Wolfram syndrome trial By Investing.com - Investing.com South Africa
AMLX Reports Promising Results from HELIOS Trial for Wolfram Syn - GuruFocus
H.C. Wainwright raises Amylyx stock target to $16 on trial hopes By Investing.com - Investing.com South Africa
H.C. Wainwright raises Amylyx stock target to $16 on trial hopes - Investing.com Nigeria
Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome - BioSpace
Amylyx Pharmaceuticals Announces Positive Long-Term Results From Phase 2 Helios Clinical Trial Of Amx0035 In People With Wolfram Syndrome - marketscreener.com
AMX0035 shows promise in Wolfram syndrome trial - Investing.com Australia
Barclays PLC Cuts Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
2025-05-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Reach Out | NDAQ:AMLX | Press Release - Stockhouse
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
HC Wainwright Increases Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target to $16.00 - Defense World
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX)April 9, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire
Shareholders that lost money on Amylyx Pharmaceuticals, Inc.(AMLX) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:AMLX) - Seeking Alpha
Here's Why We're A Bit Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Situation - Yahoo Finance
Equities Analysts Offer Predictions for AMLX Q1 Earnings - Defense World
Shareholders of Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights – AMLX - ACCESS Newswire
Amylyx Pharmaceuticals (AMLX) Target Price Raised by HC Wainwrig - GuruFocus
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at Leerink Partnrs - Defense World
Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating Upgraded by Leerink Partners - Defense World
Amylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Amylyx Pharmaceuticals Advances Clinical Trials and Strengthens Finances - TipRanks
Amylyx Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your RightsAMLX - ACCESS Newswire
Mariner LLC Decreases Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Amylyx Pharmaceuticals, Inc., Q1 2025 Earnings Call, May 08, 2025 - marketscreener.com
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
This Biotech Found Mid-Week Success Following Analyst Upgrade - The Globe and Mail
Amylyx Pharmaceuticals Shares Rise After Upgrade From Leerink - marketscreener.com
Amylyx Pharmaceuticals (AMLX) Rating Upgraded by Leerink Partner - GuruFocus
Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences - BioSpace
Lumentum Holdings To Rally Around 46%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Leerink Partners Upgrades Amylyx Pharmaceuticals (AMLX) - Nasdaq
This Logitech International Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - Benzinga
Tower Research Capital LLC TRC Has $174,000 Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (AMLX) Projected to Post Earnings on Thursday - Defense World
Amylyx (AMLX) Upgraded as Avexitide Gains Momentum | AMLX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationAMLX - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by JPMorgan Chase & Co. - Defense World
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.54%
7.58%
자본화:
|
볼륨(24시간):